Research graph
References from A multi-enzyme mimetic nanozyme sensitizes esophageal cancer to CDK4/6 inhibition via oxidative stress. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
Advances in diagnosis and management of cancer of the esophagus
10.1136/bmj-2023-074962 · 2024 · External reference
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy
10.1016/j.ccell.2025.01.003 · 2025 · External reference
Current status and perspectives of esophageal cancer: A comprehensive review
10.1002/cac2.12645 · 2025 · External reference
Oesophageal cancer
10.1016/s0140-6736(24)02226-8 · 2024 · External reference
Esophageal cancer screening, early detection and treatment: Current insights and future directions
10.4251/wjgo.v16.i4.1180 · 2024 · External reference
Current status and future prospects for esophageal cancer
10.3390/cancers15030765 · 2023 · External reference
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations
10.1016/j.ctrv.2024.102751 · 2024 · External reference
Digestive cancers: Mechanisms, therapeutics and management
10.1038/s41392-024-02097-4 · 2025 · External reference
The Role of DNA methylation in Gastrointestinal disease: An expanded review of malignant and nonmalignant gastrointestinal diseases
10.1053/j.gastro.2024.07.001 · 2025 · External reference
Integrated genomic characterization of oesophageal carcinoma
10.1038/nature20805 · 2017 · External reference
Comprehensive genomic and transcriptomic analyses reveal prognostic stratification for esophageal squamous cell carcinoma
10.1038/s41392-025-02306-8 · 2025 · External reference
Genomic analyses reveal SCN7A is associated with the prognosis of esophageal squamous cell carcinoma
10.1007/s10388-021-00898-y · 2022 · External reference
The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic
10.1038/s41588-018-0331-5 · 2019 · External reference
Epidemiology of esophageal squamous cell carcinoma
10.1053/j.gastro.2017.08.023 · 2018 · External reference
Long-Term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
10.1016/j.ccell.2024.09.009 · 2024 · External reference
Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors
10.1016/j.ccell.2016.02.006 · 2016 · External reference
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
10.1038/s41586-024-08035-2 · 2024 · External reference
Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer
10.1634/theoncologist.2020-0681 · 2020 · External reference
The CDK4/6 inhibitor revolution-a game-changing era for breast cancer treatment
10.1038/s41571-023-00840-4 · 2024 · External reference
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
10.1038/s41571-024-00935-6 · 2024 · External reference
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
10.1186/s13045-017-0467-2 · 2017 · External reference
Signaling pathways and targeted interventions for precancers
10.1038/s41392-025-02342-4 · 2026 · External reference
Personalizing cancer treatment of combined targeting of PI3K/AKT and MAPK Pathways in advanced cancer patients harboring simultaneous oncogenic alterations in both signaling pathways
10.1200/jco.2012.30.15_suppl.e13025 · 2012 · External reference
MIR497HG-Derived miR-195 and miR-497 mediate tamoxifen resistance via PI3K/AKT signaling in breast cancer
10.1002/advs.202204819 · 2023 · External reference
Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer
10.1158/0008-5472.can-15-0728 · 2016 · External reference
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas
10.1158/1078-0432.ccr-13-3310 · 2015 · External reference
Nanozymes for nanohealthcare
10.1038/s43586-024-00315-5 · 2024 · External reference
Nanomaterials with enzyme-like characteristics (nanozymes): Next-generation artificial enzymes
10.1039/c3cs35486e · 2013 · External reference
Nanozymes for Liver Disease Therapy: Advances in catalytic activity, targeting strategies, and clinical translation
10.1002/advs.74590 · 2026 · External reference
Enhancing biosafety in photodynamic therapy: Progress and perspectives
10.1039/d5cs00054h · 2025 · External reference
Targeted ROS scavenging for disease therapies using nanomaterials
10.1002/adma.202504435 · 2025 · External reference
A new insight into balancing reactive oxygen species in piezodynamic therapy
10.1002/adfm.202513106 · 2026 · External reference
Incidental vs. engineered nanoparticles in Alzheimer’s and Parkinson’s disease: Pathological pathways and therapeutic interventions
10.26599/nr.2025.94908055 · 2025 · External reference
Nanozyme-driven closed-loop regulation of antitumor immunity: From catalytic reprogramming to immunological synergy
10.26599/nr.2025.94907967 · 2025 · External reference
Designing nanozymes for in vivo applications
10.1038/s44222-024-00205-1 · 2024 · External reference
Multi-enzyme mimetic MoCu dual-atom nanozyme triggering oxidative stress cascade amplification for high-efficiency synergistic cancer therapy
10.1002/anie.202413661 · 2025 · External reference
Machine learning-assisted screening of high-entropy Sub-1 Nm nanowires for ultrasound-augmented pancatalytic tumor therapy
10.1021/jacs.5c18947 · 2026 · External reference
Atomic-precision triple-enzyme nanozyme synchronizes mitochondrial dual-pathway disruption for precision oncology
10.1002/anie.202520859 · 2026 · External reference
Fe–O–Mo site-activated nanozymes for bienzymatic/upconversion synergistic catalytic anticancer therapy
10.1002/anie.202511471 · 2025 · External reference
Design of a CuFe metal-organic framework nanozyme to enhance radiotherapy efficacy via mitochondrial oxidative stress amplification and induction of ferroptosis and cuproptosis
10.26599/nr.2025.94908023 · 2025 · External reference
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib
10.1016/j.phrs.2020.104686 · 2020 · External reference
Emerging strategies to inhibit the G1/S transition for cancer therapy
10.1158/0008-5472.can-25-0916 · 2026 · External reference
CDK4/6 Inhibitors: A novel strategy for tumor radiosensitization
10.1186/s13046-020-01693-w · 2020 · External reference
2D catalytic nanozyme enables cascade enzyodynamic effect-boosted and Ca2+ overload-induced synergistic ferroptosis/apoptosis in tumor
10.1002/adma.202312316 · 2024 · External reference
